IPO点评：康华医疗 3Q operation beat, expect strong sell-through into 4Q New report:Results in-line,shares reflect the rebounding outlook and mild growth drivers 3Q16 net profit+62% YoY on narrowed forex loss;soft CX result more than priced 3Q16 results summary:Solid results; upside surprises in 4Q16 More negatives shown in 9M16 results Orix成二股东，基本面迎来拐点 期待2017年盈利性改善，重申买入评级 3Q results:Raise TP on solid earnings(tracking 96% of FY16E)and strong insurance operation H/A:Buy/Reduce:Strong 3Q;CX headwinds to hit